Guest Julian F, Gray Elizabeth J, Szczudlo Tomasz, Magestro Matthew
Catalyst Health Economics Consultants , Northwood , UK.
Leuk Lymphoma. 2014 Aug;55(8):1870-5. doi: 10.3109/10428194.2013.854886. Epub 2014 Jan 24.
This study elicited time trade-off (TTO) and standard gamble (SG) preference values associated with four health states corresponding to response levels in chronic phase chronic myeloid leukemia (CML) from members of the general public in the UK (n = 235). Health states studied were treatment-free remission (TFR), complete molecular response (CMR, i.e. undetectable disease on treatment), molecular response and reappearance of detectable disease (i.e. relapse from TFR to molecular response requiring treatment). TFR was the most preferred health state (mean utility of 0.97 [TTO] and 0.87 [SG]) followed by CMR (mean utility of 0.96 [TTO] and 0.85 [SG]) followed by molecular response (mean utility of 0.94 [TTO] and 0.80 [SG]) followed by reappearance of detectable disease (mean utility of 0.90 [TTO] and 0.72 [SG]). SG values were significantly lower than TTO values (p < 0.001). The study demonstrated that different treatment responses may impact on the health-related quality of life of patients with chronic phase CML.
本研究从英国普通公众成员（n = 235）中获取了与慢性期慢性髓性白血病（CML）四种健康状态相对应的时间权衡（TTO）和标准博弈（SG）偏好值，这四种健康状态对应于慢性期CML的缓解水平。所研究的健康状态包括无治疗缓解（TFR）、完全分子反应（CMR，即治疗期间疾病不可检测）、分子反应以及可检测疾病再次出现（即从TFR复发至需要治疗的分子反应）。TFR是最受偏好的健康状态（TTO平均效用为0.97，SG平均效用为0.87），其次是CMR（TTO平均效用为0.96，SG平均效用为0.85），然后是分子反应（TTO平均效用为0.94，SG平均效用为0.80），最后是可检测疾病再次出现（TTO平均效用为0.90，SG平均效用为0.72）。SG值显著低于TTO值（p < 0.001）。该研究表明，不同的治疗反应可能会影响慢性期CML患者的健康相关生活质量。
